Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Finger prick vs. needle: can a drop of blood replace the lab draw?

NCT ID NCT06544070

Diagnosis Sponsor: Entia Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers are testing whether a finger-prick blood testing device, the Entia Liberty System, gives accurate results compared with standard laboratory blood tests. Participants are adults receiving systemic anti-cancer therapy who already need routine full blood count tests. They donate finger-prick samples that are analyzed on the device, and researchers compare those results with venous blood samples analyzed by a standard laboratory analyzer. The study focuses on hemoglobin, white blood cell, platelet, and neutrophil counts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Entia Liberty System, a finger-prick blood testing device
What this could lead to
If the device proves accurate, people receiving cancer treatment could one day check key blood counts with a finger prick instead of a needle draw from a vein, arm port, or PICC line.
What could go wrong
This is an early accuracy study, not a test of whether the device improves patient outcomes. Finger-prick results may not match laboratory results closely enough, especially at very low white blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Expected to start

Nov 2024

An estimate. Start dates often move.

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with a diagnosis of solid tumour cancer who are undergoing systemic anti-cancer therapy (SACT).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old at the time of study entry * Patients undergoing systemic anti-cancer therapy (SACT) * Patients capable of providing written informed consent * Patients undergoing routine Full Blood Count (FBC) laboratory blood tests as part of the standard of care Additional inclusion criteria: * Phase 1 (Longitudinal, low count data): Neutrophil Count ≤ 1.0 x109/L within 24 hours preceding consenting * Phase 2 (Low count data): Neutrophil Count ≤ 1.5 x109/L within 24 hours preceding consenting Exclusion Criteria: * History or current diagnosis of haematological malignancy * Inadequate use and understanding of the English language, requiring a translator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

More trials for these conditions

Other studies related to the condition(s) this trial covers.